Cellectar Biosciences, Inc. Series A Warrants
CLRBZ
CLRBZ was delisted on the 16th of April, 2021.
0 hedge funds and large institutions have $0 invested in Cellectar Biosciences, Inc. Series A Warrants in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $9K → $0 (-$9K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| – | -$8K | -21,755 | Closed |
|
|
2
UBS Group
Zurich,
Switzerland
| – | -$1K | -1,596 | Closed |
|
CLRBZ Hedge Fund Activity: Q2 2021 in Review
0 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. Series A Warrants (CLRBZ) for Q2 2021, worth a combined $0 — down 100% from $9K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CLRBZ and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Virtu Financial, exiting entirely with an estimated $8K sold.
- 0 institutional investors held Cellectar Biosciences, Inc. Series A Warrants (CLRBZ) as of Q2 2021, down from 2 in Q1 2021.
- Funds reported $0 of Cellectar Biosciences, Inc. Series A Warrants stock for Q2 2021, down 100% quarter-over-quarter.
- 0 funds opened new Cellectar Biosciences, Inc. Series A Warrants positions in Q2 2021 and 2 closed out, a net change of -2 holders.
- The largest Cellectar Biosciences, Inc. Series A Warrants seller in Q2 2021 was Virtu Financial, an estimated $8K sold.
Based on aggregated 13F filings for Q2 2021.